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Background and purpose: The purpose of the study was to evaluate the frequency of use of oral
antiplatelet (OAP) and anticoagulant (OAC) drugs as secondary stroke prevention among
older people in Poland and its association with sociodemographic factors, place of residence,
and concomitant cardiovascular risk factors.
Material and methods: The study group consisted of 426 subjects with a history of a previous
stroke (mean age of 81.5  8.2 years), participants of multicentre, population-based PolSe-
nior study.
Results: Among the study group, 261 people (61.3%) used at least one drug as a secondary
prevention. OAPs were regularly used by 237 people (55.6%), and OACs—by 25 people (5.9%).
The most often used drug was acetylsalicylic acid. Ticlopidine was more frequently used
than clopidogrel, and acenocoumarol was used more often than warfarin. Among all of the
concomitant cardiovascular risk factors, congestive heart failure was mostly associated with
OAP treatment, and a history of atrial ﬁbrillation—with OAC treatment. Use of drugs did not
depend on age, sex, place of residence (rural or urban), level of education and personal
income, but it was associated with the region where the respondents lived.
Conclusions: Secondary cardiovascular preventive therapy in Poland is used too rarely in
older people after stroke, and it especially concerns anticoagulant therapy in those with a
history of atrial ﬁbrillation. Structured educational programmes should be developed in
Poland to improve usage of secondary preventive therapy in the elderly.
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the study group (N = 426).
International
drug name
Number of
respondents
using the drug
n (%)
Oral antiplatelet
drugs (n = 237)
Acetylsalicylic acid 222 (52.1%)
Clopidogrel 6 (1.4%)
Ticlopidine 22 (5.2%)
Oral anticoagulant
drugs (n = 25)
Acenocoumarol 25 (5.8%)
Warfarin 11. Introduction
Stroke is a major cause of morbidity and mortality worldwide.
The incidence of stroke in Poland is estimated at 175 per
100,000 for men and 125 per 100,000 for women and is similar
to other European countries but the mortality is greater [1–5]. A
history of a previous stroke is an important risk factor for
subsequent cerebrovascular incidents. The most commonly
used drugs worldwide in secondary prevention of stroke are
oral antiplatelet agents (OAP), and among them – acetylsa-
licylic acid (ASA) [6]. The occurrence of cerebrovascular
incidents has been reduced by 25% in patients regularly
taking ASA [7,8]. Another group of medications used in
secondary prevention are oral anticoagulant (OAC) drugs,
especially recommended for prevention of recurrent stroke in
people with atrial ﬁbrillation [9].
The incidence of stroke increases signiﬁcantly with age,
and age is considered to be the strongest risk factor for
cerebrovascular disease. Little is known about the usage of
OAPs and OACs as the secondary prevention of stroke by the
elderly in our country.Table 2 – Oral antiplatelet drugs (OAPs) and oral anticoagulant d
Region All the examined subjects
n
Central 92 
South 76 
East 85 
North-West 62 
South-West 49 
North 62 
p-Value 
Table 3 – Association between level of education and seconda
Level of education All the examined subjects
n
No declared education 7 
Incomplete elementary 56 
Complete elementary 187 
Professional 48 
High school 72 
University 37 
p-Value 
OAP, oral antiplatelet drugs; OAC, oral anticoagulant drugs.Thus, the purpose of the study was to evaluate the
frequency of use of OAP and OAC drugs as secondary stroke
prevention among older people in Poland and its association
with clinical characteristics and concomitant cardiovascular
risk factors.
2. Materials and methods
The study was based on the data collected during the
implementation of a multicentre, publicly funded research
project commissioned by the Polish Ministry of Science and
Higher Education called 'Medical, psychological, sociological
and economic aspects of ageing of people in Poland (PolSenior)'
(PBZ-MEiN-9/2/2006). A detailed description of the project has
been previously published [10,11]. The project was carried out
from October 2008 to April 2012. It was approved by the Bioethics
Commission of the Medical University of Silesia in Katowice.
The study group included respondents from the PolSenior
project aged 65 years and older who answered positively to the
question: 'Have you ever been hospitalized because of a
stroke?' The following data from the general PolSenior
database were used and analysed: age, sex, place of residence
(village or city, or staying at a nursing home), level of
education, personal income, a history of cardiovascular risk
factors (coronary heart disease, previous myocardial infarc-
tion, congestive heart failure, pharmacologically treated
hypertension, a history of atrial ﬁbrillation, another previous
stroke, pharmacologically treated diabetes, pharmacologically
treated dyslipidaemia, active smoking), body mass index. The
frequency of use of drugs was based on the data collected in
the medical part of the questionnaire, including the interna-
tional and trade names of drugs taken by participants.
Statistical data analysis was performed using SAS version
9.2 (SAS Institute Inc., Gary, NC). The level of statisticalrugs (OACs) usage after stroke in different regions of Poland.
OAP or OAC
n (%)
OAP
n (%)
OAC
n (%)
48 (52.2%) 42 (45.7%) 6 (6.5%)
51 (67.1%) 48 (63.2%) 3 (4.0%)
59 (69.4%) 56 (65.9%) 4 (4.7%)
35 (56.5%) 30 (48.4%) 5 (8.1%)
27 (55.1%) 25 (51.0%) 2 (4.1%)
44 (66.1%) 36 (58.1%) 5 (8.1%)
0.12 0.05 0.83
ry prevention (n = 407, not documented in 19).
OAPs and/or OACs
n (%)
OAPs
n (%)
OACs
n (%)
3 (42.9%) 3 (42.9%) 0 (0%)
31 (55.4%) 28 (50%) 3 (5.4%)
121 (64.7%) 111 (59.4%) 11 (5.9%)
30 (62.5%) 27 (56.3%) 3 (6.3%)
48 (66.7%) 40 (55.6%) 8 (11.1%)
18 (48.7%) 18 (48.7%) 0 (0%)
0.29 0.7 0.3
Table 4 – Association between personal income and oral antiplatelet drugs (OAPs) and oral anticoagulant drugs (OACs)
usage (n = 297, not documented in 129).
Personal income zloty/mouth All the examined subjects
n
OAP or OAC
n (%)
OAP
n (%)
OAC
n (%)
Less than 1000 126 77 (61.1%) 69 (54.8%) 9 (7.1%)
1001–1500 104 74 (71.2%) 64 (61.5%) 10 (9.6%)
1501–2000 45 28 (62.2%) 25 (55.6%) 3 (6.7%)
2001 and more 22 14 (63.6%) 14 (63.6%) 0 (0.0%)
p-Value 0.43 0.69 0.47
Table 6 – Frequency of oral antiplatelet drugs (OAPs) and/
or oral anticoagulant drugs (OACs) usage in association
with presence (+) or absence (-) of concomitant cardio-
vascular risk factors (N = 426).
Risk factor OAP or OAC
n (%)
OAP
n (%)
OAC
n (%)
Previous strokesa
(+) 70 (65.42%) 63 (58.88%) 8 (7.48%)
() 179 (61.51%) 162 (55.67%) 17 (5.84%)
p-Value 0.48 0.57 0.55
Pharmacologically treated hypertension
(+) 219 (70.42%) 196 (63.02%) 24 (7.72%)
() 42 (36.52%) 41 (35.65%) 1 (0.87%)
p-Value <0.01 <0.01 <0.01
Previous myocardial infarct
(+) 58 (75.32%) 50 (64.94%) 9 (11.69%)
() 189 (57.62%) 174 (53.05%) 15 (4.57%)
p-Value <0.01 0.06 0.03
History of atrial ﬁbrillation
(+) 73 (69.52%) 53 (50.48%) 21 (20.00%)
() 168 (57.73%) 164 (56.36%) 4 (1.37%)
p-Value 0.03 0.30 <0.01
Coronary heart disease (without myocardial infarct)
(+) 53 (68.83%) 45 (58.44%) 8 (10.39%)
() 195 (59.63%) 181 (55.35%) 15 (4.59%)
p-Value 0.14 0.62 0.06
Congestive heart failure
(+) 52 (75.36%) 45 (65.22%) 7 (10.14%)
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test, Fisher exact test, the Shapiro–Wilk test, the Student t-test,
and the Wilcoxon rank sum test. A model of logistic regression
was used to analyse the association between cardiovascular
risk factors and treatment with OAP and/or OAC drugs.
3. Results
Among all the PolSenior participants aged 65 and older
(n = 4979), 426 people (8.6%) answered 'Yes' to the question:
'Have you ever been hospitalized because of a stroke?' and they
were included in the analysis. The study group consisted of 236
men (55.4%) and 190 women (44.6%). The mean age of the
examined subjects was 81.5  8.2 years, similar for men and
women (81.1  8.7 vs. 81.9  7.5 years p = 0.33, respectively).
Among all the patients with a history of a stroke, 261
subjects (61.3%) used at least one drug as the secondary
prevention. Oral antiplatelets were regularly used by 237
people (55.6%); 224 (94.5%) were taking one drug, and 13 (5.5%)
were taking two drugs. Oral anticoagulants were regularly
used by 25 subjects (5.9%) (one respondent was taking two
OACs). Antiplatelet therapy and anticoagulant therapy were
simultaneously applied by only one person (Table 1).
The percentage of women after stroke using OAPs and/or
OACs (61.1%; n = 116) was similar to the corresponding
percentage of men after stroke (61.4%; n = 145) ( p = 0.93). AlsoTable 5 – Frequency of concomitant cardiovascular risk
factors in the study group (n = 426).
Risk factor n (%) Not documented
n (%)
Previous strokesa 107 (25.1%) 28 (6.6%)
Pharmacologically treated
hypertension
311 (73%) –
Previous myocardial infarct 77 (18.1%) 21 (4.9%)
History of atrial ﬁbrillation 105 (22.6%) 30 (7%)
Coronary heart disease
(without myocardial infarct)
77 (18.1%) 22 (5.2%)
Congestive heart failure 69 (16.2%) 25 (5.6%)
Pharmacologically treated
diabetes
89 (20.9%) 130 (30.5%)
Pharmacologically treated
dyslipidaemia
153 (35.9%) –
Current smoker 31 (7.3%) 4 (0.9%)
Overweight/obesity
(BMI  25 kg/m2)
248 (58.2%) 82 (19.2%)
BMI, body mass index.
a Two or more incidents of stroke.
() 193 (58.13%) 178 (53.61%) 16 (4.82%)
p-Value 0.01 0.08 0.09
Pharmacologically treated diabetes
(+) 64 (71.9%) 58 (65.2%) 6 (6.7%)
() 129 (62.3%) 114 (55.1%) 16 (7.7%)
p-Value 0.11 0.11 1.00
Pharmacologically treated dyslipidaemia
(+) 120 (78.4%) 106 (69.3%) 15 (9.8%)
() 141 (51.7%) 131 (48.0%) 10 (3.7%)
p-Value <0.01 <0.01 0.02
Current smoker
(+) 18 (58.1%) 16 (51.6%) 2 (6.5%)
() 241 (61.6%) 220 (56.3%) 22 (5.6%)
p-Value 0.69 0.62 0.69
Overweight/obesity
(BMI  25 kg/m2)
(+) 163 (65.7%) 141 (56.9%) 23 (9.3%)
() 60 (62.5%) 58 (60.4%) 2 (2.1%)
p-Value 0.57 0.55 0.02
Sex
Female 116 (61.1%) 102 (53.7%) 15 (7.9%)
Male 145 (61.4%) 135 (57.2%) 10 (4.2%)
p-Value 0.96 0.47 0.15
BMI, body mass index.
a Two or more incidents of stroke; drugs, (+), risk factor present;
(), risk factor absent.
Table 7 – Association of concomitant cardiovascular risk factors with oral antiplatelet drugs (OAPs) and/or oral
anticoagulant drugs (OACs) treatment (N = 426).
Risk factor OAP or OAC OAP OAC
OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
Previous strokesa 1.22
(0.58–2.57)
0.6 1.24
(0.62–2.49)
0.55 0.82
(0.21–3.31)
0.78
Pharmacologically treated hypertension 1.85
(0.87–3.94)
0.11 1.73
(0.83–3.6)
0.14 3.87
(0.35–43.26)
0.27
Previous myocardial infarct 2.61
(0.89–7.66)
0.08 2.3
(0.94–5.62)
0.07 0.84
(0.2–3.5)
0.81
History of atrial ﬁbrillation 1.11
(0.51–2.42)
0.79 0.38
(0.18–0.78)
0.01 31.47
(6.59–150.16)
<0.01
Coronary heart disease (without myocardial infarct) 0.67
(0.28–1.64)
0.39 0.64
(0.28–1.46)
0.29 1.21
(0.3–4.95)
0.79
Congestive heart failure 3.02
(1.02–8.88)
0.05 2.69
(1.06–6.8)
0.04 0.46
(0.1–2.12)
0.32
Pharmacologically treated diabetes 1.74
(0.86–3.52)
0.12 1.73
(0.9–3.33)
0.1 0.61
(0.15–2.48)
0.49
Pharmacologically treated dyslipidaemia 2.35
(1.18–4.65)
0.01 1.27
(0.68–2.38)
0.46 10.91
(2.4–49.65)
<0.01
Current smoker 0.65
(0.24–1.75)
0.39 0.72
(0.28–1.87)
0.5 0.73
(0.06–9.39)
0.81
Overweight/obesity
(BMI  25 kg/m2)
0.88
(0.43–1.8)
0.72 0.72
(0.36–1.44)
0.36 5.89
(0.57–61.23)
0.14
Sex (male/female) 1.69
(0.82–3.49)
0.16 1.89
(0.96–3.7)
0.06 0.36
(0.08–1.51)
0.16
OR, odds ratio; CI, conﬁdence interval.
a Two or more incidents of stroke.
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secondary stroke prevention.
Most of analysed group lived in cities (61.2%; n = 264). There
was no difference in using OAP and/or OAC drugs between
urban (61.4%; n = 162) and rural (61.1%; n = 99) residents
( p = 0.96). In the study group, there were 8 residents of nursing
houses (1.9%) and 5 of them (62.5%) used OAP and/or OAC
drugs.
We observed signiﬁcant differences in the frequency of
usage of antiplatelet drugs, depending on the province where
the respondents lived. Oral antiplatelets were mostly applied
by people from East (65.9% of respondents living in this region)
and South (63.2%), while the lowest amount was applied by
people living in Central region (45.7%), and North-West (48.4%).
A detailed analysis of OAPs and/or OACs usage in different
Polish regions is presented in Table 2.
No correlation was found between the frequency of use of
OAPs and/or OACs after stroke and the level of education
(Table 3) or personal income (Table 4).
The frequency of cardiovascular risk factors in the whole
study group is shown in Table 5. The association between use
of OAP and/or OAC drugs and presence or absence of
cardiovascular risk factors is presented in Table 6. Among
all of the cardiovascular risk factors, congestive heart failure
was most associated with OAP treatment, and a history of
atrial ﬁbrillation—with OAC treatment (Table 7).
4. Discussion
The study was based on a countrywide representative sample
of Poles aged 65 years or older and presented the prevalence ofsecondary preventive therapy among a group of respondents
after at least one episode of stroke. We found that in Poland
about 60% of older people after stroke were applying
secondary pharmacological prevention, and it seemed to be
less than in other Western European countries [12–14],
especially in people with atrial ﬁbrillation [12]. Only one ﬁfth
of older Polish people with atrial ﬁbrillation used OACs.
According to the Swedish Stroke Register more than 30% of
people after stroke with atrial ﬁbrillation are applying OACs
[12]. It should be stressed that the Swedish Stroke Register
population was younger than in our study (mean age about
75 years).
Both worldwide and in Poland, the most popular drug used
as secondary cardiovascular prevention is ASA. We also
observed that ticlopidine was used more frequently in Poland
than clopidogrel, probably because of the ﬁnancial reasons
(until recently, the preparations of clopidogrel in Poland were
much more expensive than ticlopidine). Dual antiplatelet
therapy was used by about 5% of respondents and the most
common combination was ASA with ticlopidine.
We found that dipyridamole was not at all used in Poland.
This drug is recommended in combination with ASA in
patients after stroke who used ASA before or in patients after
recurrent strokes [15,16]. The monthly cost of such combina-
tion is much higher than the therapy with ASA alone. In our
country, not only the price, but also low availability of
dipyridamole (it is not dispensed in Polish pharmacies), poses
the problem. For instance, in Sweden it is prescribed in more
than 10% of people discharged from the hospital after an
ischaemic stroke [13].
We noticed that acenocoumarol was much more popular
than warfarin in Poland, contrary to the situation in other
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low availability and high price of the drug for the patient in the
period when the study was conducted.
Contrary to our previous paper [17], concerning general
usage of OAPs and OACs in the whole PolSenior population, we
found no association between applying of secondary cardio-
vascular prevention and age, sex, place of residence, level of
education, and personal income.
However, our study revealed signiﬁcant differences in
the frequency of usage of analysed drugs, depending on the
region where the respondents lived. In some regions, the
prevalence of secondary pharmacological prevention was
much lower than the average. It especially concerned
Central region and North-West region. The number of people
living in particular regions was rather low and it might
inﬂuence the statistics but it should be checked in further
examinations.
5. Limitations of the study
The reasons for abandonment of therapy (contraindications),
the type of the stroke (ischaemic or haemorrhagic), and the
time from the stroke could not be established because of the
lack of data.
6. Conclusions
1. In Poland secondary cardiovascular preventive therapy is
used too rarely in older people after stroke, and it especially
concerns anticoagulant therapy in those with a history of
atrial ﬁbrillation.
2. The frequency of use of OAPs and OACs as the secondary
prevention in elderly people is not associated with age, sex,
place of residence (urban or rural), level of education, and
personal income.
3. The usage of OACs and/or OACs depends on the region
where the respondents lived.
4. Among all the analysed drugs, the most popular is ASA.
Ticlopidine is more popular than clopidogrel, and aceno-
coumarol—than warfarin. Dipiridamole is not used in
Poland as secondary prevention.
5. Among all of the concomitant cardiovascular risk factors,
congestive heart failure was most associated with OAP
treatment in the elderly after stroke, and a history of atrial
ﬁbrillation—with OAC treatment. Structured educational
programmes should be developed in our country to improve
usage of secondary preventive therapy in the elderly.
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